Foster Eric Duane
Known title: Chief Commercial OfficerCIK: 0002034148
Associated companies
Transaction History
| ARDX | ▼ Sell | Open Market | 2,598 | $10K | 8/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 3,389 | $13K | 8/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,575 | $10K | 8/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 3,166 | $20K | 5/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,427 | $15K | 5/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,405 | $15K | 5/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 9,176 | $54K | 2/20/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,261 | $7K | 2/20/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 1 | $6 | 2/20/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 1 | $6 | 2/20/2026 | View on chart |
| ARDX | ▲ Buy | Grant | 137,945 | $0 | 1/23/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,814 | $32K | 11/21/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 15,308 | $91K | 8/21/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,507 | $10K | 5/20/2025 | View on chart |
| ARDX | ▲ Buy | Grant | 136,680 | $0 | 2/25/2025 | View on chart |
| ARDX | ▲ Buy | Grant | 180,000 | $0 | 8/8/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Ardelyx shares IBSRELA real-world data at ACG 2026
Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.
Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.